Prognostic value of pretreatment levels of tumor markers for hepatocellular carcinoma on survival after curative treatment of patients with HCC

Journal of Hepatology

Volumn 49, Issue 2, 2008, Pages 223-232

  Toyoda, Hidenori ^a   Kumada, Takashi ^a   Kaneoka, Yuji ^a   Osaki, Yukio ^b   Kimura, Toru ^b   Arimoto, Akira ^b   Oka, Hiroko ^c   Yamazaki, Osamu ^c   Manabe, Takao ^c   Urano, Fumihiro ^d   Chung, Hobyung ^e   Kudo, Masatoshi ^e   Matsunaga, Takashi ^f  

^a OGAKI MUNICIPAL HOSPITAL   (Japan)

^b OSAKA RED CROSS HOSPITAL   (Japan)

^c OSAKA CITY GENERAL HOSPITAL   (Japan)

^d TOYOHASHI MUNICIPAL HOSPITAL   (Japan)

^e KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^f OSAKA MEDICAL CENTER FOR CANCER AND CARDIOVASCULAR DISEASES   (Japan)

Author keywords

Curative treatment; Hepatocellular carcinoma; Recurrence; Survival; Tumor markers

Indexed keywords

DECARBOXYPROTHROMBIN; TUMOR MARKER;

ADULT; AGED; ARTICLE; CANCER SURVIVAL; CONTROLLED STUDY; FEMALE; HUMAN; LENTIL; LIVER CELL CARCINOMA; LIVER FUNCTION; LIVER RESECTION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; TREATMENT OUTCOME;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; CARCINOMA, HEPATOCELLULAR; CATHETER ABLATION; FEMALE; HEPATECTOMY; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PLANT LECTINS; PROGNOSIS; PROTEIN PRECURSORS; PROTHROMBIN; SURVIVAL ANALYSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 46149115142     PISSN: 01688278     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jhep.2008.04.013     Document Type: Article

References (25)

1. El-Serag H.B., and Mason A.C. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 340 (1999) 745-750
2. El-Serag H.B., Davila J.A., Petersen N.J., and McGlynn K.A. The continuing increase in the incidence of hepatocellular carcinoma in the United States: an update. Ann Intern Med 139 (2003) 817-823
3. Tsukuma H., Hiyama T., Tanaka S., Nakao M., Yabuuchi T., Kitamura T., et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Engl J Med 328 (1993) 1797-1801
4. Taketa K., Sekiya C., Namiki N., Akamatsu K., Ohta Y., Endo Y., et al. Lectin-reactive profiles of alpha-fetoprotein characterizing hepatocellular carcinoma and related conditions. Gastroenterology 99 (1990) 508-518
5. Liebman H.A., Furie B.C., Tong M.J., Blanchard R.A., Lo K.J., Lee S.D., et al. Des-gamma-carboxy (abnormal) prothrombin as a serum marker of primary hepatocellular carcinoma. N Engl J Med 310 (1984) 1427-1431
6. Fujiyama S., Tanaka M., Maeda S., Ashihara H., Hirata R., and Tomita K. Tumor markers in early diagnosis, follow-up and management of patients with hepatocellular carcinoma. Oncology 62 (2002) S57-S63
7. Toyoda H., Kumada T., Kiriyama S., Sone Y., Tanikawa M., Hisanaga Y., et al. Prognostic significance of simultaneous measurement of three tumor markers in patients with hepatocellular carcinoma. Clin Gastroenterol Hepatol 4 (2006) 111-117
8. Toyoda H., Kumada T., Osaki Y., Oka H., Urano F., Kudo M., et al. Staging hepatocellular carcinoma by a novel scoring system (BALAD score) based on serum markers. Clin Gastroenterol Hepatol 4 (2006) 1528-1536
9. Shiina S., Teratani T., Obi S., Sato S., Tateishi R., Fujishima T., et al. A randomized controlled trial of radiofrequency ablation with ethanol injection for small hepatocellular carcinoma. Gastroenterology 129 (2005) 122-130
10. Pugh R.N.H., Murray-Lyon I.M., Dawson J.L., Pietroni M.C., and Williams R. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 60 (1973) 646-649
11. Torzilli G., Minagawa M., Takayama T., Inoue K., Hui A.M., Kubota K., et al. Accurate preoperative evaluation of liver mass lesions without fine-needle biopsy. Hepatology 30 (1999) 889-893
12. Kudo M. Imaging diagnosis of hepatocellular carcinoma and premalignant/ borderline lesions. Semin Liver Dis 19 (1999) 297-309
13. Taketa K., Endo Y., Sekiya C., Tanikawa K., Koji T., Taga H., et al. A collaborative study for the evaluation of lectin-reactive alpha-fetoprotein in early detection of hepatocellular carcinoma. Cancer Res 53 (1993) 5419-5423
14. Yamashita F., Tanaka M., Satomura S., and Tanikawa K. Prognostic significance of Lens culinaris agglutinin A-reactive alpha-fetoprotein in small hepatocellular carcinoma. Gastroenterology 111 (1996) 996-1001
15. Mita Y., Aoyagi Y., Yanagi M., Suda T., Suzuki Y., and Asakura H. The usefulness of determining des-gamma-carboxy prothrombin by sensitive enzyme immunoassay in the early diagnosis of patients with hepatocellular carcinoma. Cancer 82 (1998) 1643-1648
16. Okuda H., Nakanishi T., Takatsu K., Saito A., Hayashi N., Watanabe K., et al. Measurement of serum levels of des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity. Cancer 85 (1999) 812-818
17. Nomura F., Ishijima M., Kuwa K., Tanaka N., Nakai T., and Ohnishi K. Serum des-gamma-carboxy prothrombin levels determined by a new generation of sensitive immunoassays in patients with small-sized hepatocellular carcinoma. Am J Gastroenterol 94 (1999) 650-654
18. Kaplan E.L., and Meier P. Non parametric estimation for incomplete observation. J Am Stat Assoc 53 (1958) 457-481
19. Petro R., and Pike M.C. Conservation of the approximation (0-E2)/E in the log rank test for survival data on tumor incidence data. Biometrics 29 (1973) 579-584
20. Cox D. Regression models and life tables. J R Stat Soc 34 (1972) 187-220
21. Oka H., Tamori A., Kuroki T., Kobayashi K., and Yamamoto S. Prospective study of alpha-fetoprotein in cirrhotic patients monitored for development of hepatocellular carcinoma. Hepatology 19 (1994) 61-66
22. Ikeda K., Saitoh S., Koida I., Arase Y., Tsubota A., Chayama K., et al. A multivariate analysis of risk factors for hepatocellular carcinogenesis: a prospective observation of 795 patients with viral and alcoholic cirrhosis. Hepatology 18 (1993) 47-53
23. Hu K.-Q., Kyulo N.L., Lim N., Elhazin B., Hillebrand D.J., and Bock T. Clinical significance of elevated alpha-fetoprotein (AFP) in patients with chronic hepatitis C, but not hepatocellular carcinoma. Am J Gastroenterol 99 (2004) 860-865
24. Koike Y., Shiratori Y., Sato S., Obi S., Teratani T., Imamura M., et al. Des-gamma-carboxy prothrombin as a useful predisposing factor for the development of portal venous invasion in patients with hepatocellular carcinoma: a prospective analysis of 227 patients. Cancer 91 (2001) 561-569
25. Spangenberg H.C., Thimme R., and Blum H.E. Serum markers of hepatocellular carcinoma. Semin Liver Dis 26 (2006) 385-390